Explain the role of driver mutations and biomarkers in the pathogenesis and treatment selection of NSCLC in clinical pathway Apply clinical guidelines, recent updates, and economic variables guiding NSCLC treatment protocols and their significance for NSCLC clinical pathways Implement strategies that align evidence-based best practices and personalized medicine into an interdisciplinary setting for NSCLC care to optimize patient outcomes and streamline treatment pathways
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 104 Windsor Center Drive
Pricing
CME included with membership · $99–598/yr
| New Membership – Standard | $349/yr |
| New Membership – Standard (2-year) | $598/yr |
| New Membership – Military/VA | $259/yr |
| New Membership – Student/Resident | $149/yr |
| Renewal Membership – Standard | $249/yr |
| Renewal Membership – Standard (2-year) | $478/yr |
+27 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Child & Adolescent Psychiatry
- Clinical Informatics
- Communication & Shared Decision-Making
- General & Adult Psychiatry
- General Surgery
- Interventional Radiology
- Mood & Anxiety Disorders
- Neurology
- Neuroradiology
- Nuclear Medicine
- Pain Medicine
- Pediatric Neurology
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Sleep Medicine
- Cross-Specialty
- Medical Subspecialties
- Neurology
- Pain & Palliative
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 0.75 credits
- MOC · Up to 0.75 points
- Commercial Support
-
ReleasedAug 21, 2026
-
Last day to claim creditFeb 6, 2027 4 months left
-
National Comprehensive Cancer Network Targeted Therapy for Early-Stage, EGFR- and ALK-Positive Non-Small Cell Lung Cancer: Precision Treatment and Strategies
-
PRIME Education, Inc. (PRIME®) Integrating Multidisciplinary Insights Into Treatment Decisions in Resectable NSCLC
-
American Association for Thoracic Surgery Plenary Session I: Lung Cancer Advances: Evolving Treatment Paradigms in Operable NSCLC| Presented at the 2025 International Thoracic Surgical Oncology Summit
